Viridian Therapeutics, Inc.\DE (VRDN) Other financing activities (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Other financing activities of $287.9 million for Q4 2025, up 176.09% year-over-year from $104.3 million in Q4 2024, and up 57917.67% quarter-over-quarter from -$498000.0 in Q3 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Other financing activities (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Other financing activities history runs 12 years deep, the most recent figure standing at $287.9 million for Q4 2025.
- In Q4 2025, Other financing activities rose 176.09% year-over-year to $287.9 million; the TTM figure through Mar 2026 stood at $287.4 million (up 4028.61% YoY), while the FY2025 annual figure was $289.1 million, up 5308.91% from the prior year.
- Other financing activities for Q4 2025 stood at $287.9 million, up from -$498000.0 in the prior quarter.
- The five-year high for Other financing activities was $383.4 million in Q3 2024, with the low at -$378.4 million in Q4 2024.
- The 5-year median for Other financing activities is $908000.0 (2022), against an average of $19.7 million.
- The sharpest annual moves came in 2023 and 2024: Other financing activities tumbled 1035.13% in 2023, then surged 4615.29% in 2024.
- Viridian Therapeutics, Inc.\DE's Other financing activities stood at -$900000.0 in 2021, then rose by 19.44% to -$725000.0 in 2022, then sank by 1071.17% to -$8.5 million in 2023, then sank by 4356.54% to -$378.4 million in 2024, then jumped by 176.09% to $287.9 million in 2025.
- Business Quant data shows VRDN's Other financing activities at $287.9 million in Q4 2025, -$498000.0 in Q3 2025, and $1.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 137.39 Mn |
| Jun 30, 2026 | 137.39 Mn |
| Mar 31, 2026 | 6.36 Mn |
| Mar 31, 2026 | 6.36 Mn |
| Dec 31, 2025 | 287.93 Mn |
| Dec 31, 2025 | 287.93 Mn |
| Sep 30, 2025 | -498,000.00 |
| Sep 30, 2025 | -498,000.00 |
| Mar 31, 2025 | 1.62 Mn |
| Mar 31, 2025 | 1.62 Mn |
| Dec 31, 2024 | -378.41 Mn |
| Dec 31, 2024 | -378.41 Mn |
| Sep 30, 2024 | 383.39 Mn |
| Sep 30, 2024 | 383.39 Mn |
| Jun 30, 2024 | 356,000.00 |
| Jun 30, 2024 | 356,000.00 |
| Sep 30, 2023 | -8.49 Mn |
| Sep 30, 2023 | -8.49 Mn |
| Jun 30, 2023 | 8.13 Mn |
| Jun 30, 2023 | 8.13 Mn |